Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory ...
A few baseline characteristics can predict the need for recurrent endoscopic sinus surgery among patients with CRSwNP.
Hosted on MSN1mon
China’s NMPA approves GSK’s Nucala for CRSwNP treatmentThe China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...
Simultaneously, the three regulators are also reviewing a second potential indication for depemokimab as an add-on therapy for chronic rhinosinusitis with nasal polyps (CRSwNP). GSK has said ...
Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 million people in the country. This approval ...
AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been ...
Concerning CRSwNP, GSK intends to secure approval in adults. Similar regulatory filings for the drug have also been validated for review in China and Japan. If approved, depemokimab will be the ...
EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...
GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...
GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...
If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing Submissions based on data from positive SWIFT and ANCHOR trials SWIFT-1 and -2 showed depemokimab reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results